secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2021-10-06T23:59:59+00:00
Accession:  0001193125-21-292635
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pieris Pharmaceuticals appoints Tom Bures as CFO, Ahmed Mousa as Chief Business Officer
--------------------------------------------------------------------------------

- Tom Bures promoted to CFO effective Oct 6, 2021; previously VP Finance and Treasurer.
- Ahmed Mousa promoted to Chief Business Officer & General Counsel; previously SVP Corporate Operations and GC.
- Bures base salary $370k, Mousa base $385k; each eligible for up to 40% annual bonus.
- Severance: 9 months base for without-cause; change of control: 12 months base + target bonus + full vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312521292635/0001193125-21-292635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312521292635/d206195d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-292635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer